Disclosure

23-Gene Signature
Housekeeper Group
Algorithm
SCORE
Immune Signaling Group IRF1 CCL5 CXCL9 CXCL10 CD38 LCP2 PTPRC SELL S100A Group S100A7 S100A8 S100A9 S100A12 PI3 PRAME PRAME (2 Amplicons)
• In a recent validation of the score to outcome-proven diagnoses, we analyzed the test in:
• 83 nevi with median 7+ years event-free follow-up • 99 primary cutaneous melanomas with proven distant metastases
• Specificity = 96.2%, Sensitivity = 93.8%
• False negative results occurred in 6 of 99 melanomas
• 3 of the 6 were desmoplastic melanomas
Introduction
• To assess the sensitivity and specificity of the gene signature in the differentiation of desmoplastic melanoma (DM) and its variants from benign simulators such as sclerotic and desmoplastic variants of melanocytic nevi.
Objective
• Database searched for any of the following terms in the diagnosis or differential diagnosis fields:
• 40 cases identified.
• H&E-stained sections of all 40 cases were reviewed independently by 2 dermatopathologists and diagnoses were assigned.
Cohort and Testing
• An additional 10 lesions were retrieved from the pathology archives of Memorial Sloan Kettering Cancer Center and submitted (blinded to initial diagnosis) for gene expression testing.
• The final diagnoses for all cases were supported by one or more of the following:
• Histopathologic features • Follow-up / outcome information • Gene copy number changes detected by SNP array.
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• 27 nevi • Sensitivity of the gene signature for desmoplastic melanomas appears to be lower than for other melanoma variants
• In the small subset of cases with both gene signature and SNP array results, performance was similar
• All currently available molecular methods appear to have lower sensitivity for desmoplastic melanoma
• A positive result is confirmatory; a negative result must be considered within context of other clinical and histopathologic data Conclusions
